Trial Profile
An Open Randomized Phase I/II Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1-infected Mothers.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV DNA vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Sep 2018 Status changed from active, no longer recruiting to completed.
- 14 Mar 2012 Planned end date changed from 1 Oct 2011 to 1 May 2012 as reported by Pan-African Clinical Trials Registry.
- 03 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by Pan-African Clinical Trials Registry.